Acoramidis Reduces Atrial Fibrillation Burden in ATTR-CM: ESC 2025 Insights

In this ESC 2025 CardioNerds discussion, CardioNerds Fellows Drs. Georgia Vasilakis Tsatiris and Anna Radhakrishnan interview Dr. Kevin Alexander, Assistant Professor of Cardiovascular Medicine at Stanford, about the latest findings from the ATTRibute-CM trial. Dr. Alexander, an expert in cardiac amyloidosis, explains that the phase 3 trial evaluated the efficacy of Acoramidis—a highly selective Transthyretin stabilizer—in patients with wild-type or hereditary ATTR-CM, showing significant benefits in cardiovascular outcomes.

Advertisement
Advertisement
Advertisement
Editorial Board